KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Debt: 2012-2025

Historic Total Debt for Halozyme Therapeutics (HALO) over the last 12 years, with Sep 2025 value amounting to $1.5 billion.

  • Halozyme Therapeutics' Total Debt rose 0.44% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 0.44%. This contributed to the annual value of $1.5 billion for FY2024, which is 0.44% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Total Debt is $1.5 billion, which was up 0.11% from $1.5 billion recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Total Debt high stood at $1.5 billion for Q3 2025, and its period low was $89.0 million during Q1 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Total Debt value was $1.5 billion (recorded in 2024), while the average stood at $1.5 billion.
  • Per our database at Business Quant, Halozyme Therapeutics' Total Debt surged by 3,014.45% in 2021 and then declined by 0.46% in 2023.
  • Halozyme Therapeutics' Total Debt (Quarterly) stood at $876.7 million in 2021, then skyrocketed by 71.80% to $1.5 billion in 2022, then fell by 0.45% to $1.5 billion in 2023, then climbed by 0.44% to $1.5 billion in 2024, then climbed by 0.44% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.5 billion during Q1 2025.